Hadasit Bio-Holdings Ltd. (“HBL”) was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. For the first time, public investment is allowed to participate in companies based on IP generated by Israel’s foremost medical research center – the Hadassah University Hospital (“Hadassah”), which is responsible for the majority of Israel’s hospital-based translational research.
Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - for the first time, public investment was allowed to participate in companies based on IP generated by Israel's foremost medical research center - the Hadassah University Hospital ("Hadassah"), which is responsible for the majority of Israel's hospital-based translational research.
HBL focuses on funding early-stage promising pharmaceutical companies, in pre-clinical and early phases of clinical studies.
HBL is a unique opportunity. It offers a fertile environment for the wedding of science, medicine, academia and business – within the framework of which a cluster of companies, focusing on a variety of therapeutic areas, will enjoy the benefits of a public offering. This framework serves to address an inherent problematic characteristic of investment in early-stage biotech by distributing both risk and the chance of success amongst a number of companies.
HBL provides investment exposure to a selected portfolio of 3 biotech companies. The companies operate in the fields of Immuno-Oncology , Ophthalmology, and Inflammatory Diseases. HBL holdings in its portfolio companies range from partial ownership to minority stakes. The holding entity offers investors and partners a unique risk-reward profile.
KAHR is a clinical stage company developing novel immune-recruiting therapies that treat cancer at the source by unleashing the synergistic power of the body’s innate and adaptive immune responses. The company is leveraging its proprietary MIRP technology (multifunctional immuno-recruitment protein) to promote better and safer therapeutic avenues by developing new immuno-recruitment drugs that unmask cancer camouflage mechanisms, while simultaneously recruiting a targeted immune response.
Enlivex (NASDAQ:ENLV) is developing off-the-shelf, universal, macrophage reprogramming cell therapies for lifethreatening diseases.
As a clinical-stage company focused on macrophage reprogramming, Enlivex intend to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, Sepsis and other indications.
The pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach.
CellCure Neurosciences Ltd., a Lineage subsidiary which began at the Hadassah Medical Center in Israel, has developed cell growth, expansion, and reproducibility protocols required to manufacture specialized cell types on a commercial scale.
Cell Cure technology is based on human embryonic stem cells (hESC), which, for the first time in the history of medicine, open the door to industrial-scale manufacture of any cell type in the human body. Cell Cure is using these powerful stem cells to develop OpRegen for the treatment of ocular disorders, including advanced dry age-related macular degeneration (dry AMD). On December 20, 2021, Lineage and Cellcure entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech, a member of the Roche Group, for the development and commercialization of OpRegen for the treatment of ocular disorders.
HBL is a publicly traded subsidiary of Hadasit Medical Research Services & Development Ltd (https://www.hadasit.org.il), the technology transfer company of Hadassah Medical Center in Jerusalem. Hadasit transform the cutting-edge research coming out of Hadassah into marketable medical technologies.
Since its inception, Hadassah’s pacesetting progress has set the standard for medicine in Israel – the standard of excellence. Since the establishment of Hadassah’s first hospital on Jerusalem’s Neviim Street (Street of the Prophets) – a gift of the Rothschild family in 1918 – the Hadassah University Medical Center has expanded to include two University hospitals in Jerusalem – located on Mt. Scopus and in Ein Kerem. The flagship of Hadassah, the Women’s Zionist Organization of America, the two hospitals have 1,000 beds, 31 operating theaters, nine specially oriented intensive care units and five schools of allied medical professions, owned and operated in collaboration with the Hebrew University.
Hadassah’s physicians and scientists are actively engaged in a wide variety of extensive basic and clinical research projects, looking for new ways to treat current conditions. More than half of all hospital research conducted in Israel is conducted at Hadassah. Each department incorporates research units and the hospital houses many interdisciplinary research centers. Both hospitals have several Centers of Excellence: brain trusts of scientists and physicians, integrating clinical care with the latest laboratory lessons.
Hadasit, Hadassah’s Technology Transfer Company, promotes and commercializes the intellectual property and R&D capabilities continuously generated by Hadassah physicians and scientists. Hadasit’s successful enterprising of Hadassah’s biomedical technology – including novel therapeutics, diagnostics and devices – has gained Hadassah global recognition.